U.S., May 28 -- ClinicalTrials.gov registry received information related to the study (NCT07608029) titled 'Xiaochaihu Granules for Depression After Allogeneic Hematopoietic Stem Cell Transplantation' on May 03.
Brief Summary: This is a single-center, prospective, randomized, dose-escalation Phase II clinical study. A total of 46 patients with newly diagnosed depression following allogeneic hematopoietic stem cell transplantation (allo-HSCT) will be enrolled.
Participants will be randomly assigned to receive different doses of Xiaochaihu Granules in addition to standard post-transplant care for 100 days. The primary objective is to evaluate the efficacy of Xiaochaihu Granules in improving depressive symptoms. Secondary objectives include ...